

| Department:   | Pharmacy Management                          | Original<br>Approval: | 10/26/2006 |
|---------------|--|-----------------------|------------|
| Policy No:    | PM556  | Last Approval:        | 01/24/2025 |
| Policy Title: | Medication Therapy Management Program Policy |                       |            |
| Approved By:  | Clinical Services Leadership Team            |                       |            |
| Dependencies: | N/A  |                       |            |

### Purpose

This policy describes the way Community Health Plan of Washington (CHPW) administers its Centers for Medicare and Medicaid Services (CMS)-approved Medication Therapy Management Program (MTMP).

### Policy

CHPW engages its Pharmacy Benefit Manager (PBM) to implement and maintain the MTMP. The MTMP is designed to improve members' use of their medications. This program is administered by the trained clinical pharmacist or licensed pharmacy intern under the supervision of a pharmacist. The program is designed to meet CMS MTMP requirements for designated calendar years and follows CMS requirements regarding mid-year changes to the approved MTMP.

#### Eligibility

Once the member becomes Part D eligible, the member's prescription claims history will be scanned to determine eligibility for enrollment into the MTMP.

A member must meet ALL three of the following criteria to be eligible for the MTMP:

- The member has 3 or more Medicare-targeted chronic disease states;
- The member has filled 8 or more covered Part-D chronic/maintenance medications, and;
- The member is likely to incur annual costs for covered Part-D medications that exceed a predetermined level as specified by the Secretary of the Department of Health and Human Services (DHHS).

#### **Enrollment Methods**

Members meeting the above MTMP eligibility criteria may enroll in the following ways:

• Long-Term Care (LTC) patients are automatically enrolled.



• The enrollment method is by member opt-out only for non-LTC patients.

For any enrollment method, a member, their authorized representative, or their physician may request at any time that the member's participation in the program be discontinued.

#### **Program Structure**

The MTMP is managed and maintained by the PBM. All clinical MTMP enhancements or changes are reviewed by an external, independent group of licensed and practicing pharmacists and physicians with expertise in the relevant field of review and/or the elderly. A member who meets the MTMP criteria as described above will be automatically enrolled in the program and sent a letter explaining the program. This letter invites the member to participate in a free one-on-one consultation session with a pharmacist or licensed pharmacy intern [i.e., Comprehensive Medication Review (CMR)] and gives them the opportunity to opt out if desired. Members can request the CMR or opt out by returning an enclosed form or calling a toll-free number provided in the letter. A pharmacist or licensed pharmacy intern may make calls to supplement the letter in which they may offer a member to participate in a CMR or provide an opportunity to opt-out of the MTMP. During the CMR, the pharmacist and/or intern will:

- conduct a comprehensive discussion of all medications (including over-the-counter medications) with the member;
- discuss disease specific issues and answer any questions the member may have, and;
- identify/discuss potential and actual medication related problems and suggest targeted action plans to address each of the problems.

After the CMR, the member will be mailed a completed Personal Medication Record (PMR) and Medication Action Plan (MAP) in the CMS standardized format (CMS-10396).

The PBM pharmacist who performs the CMR communicates medication related issues identified during the CMR with the member's physician via phone or fax to discuss the issues. The PBM pharmacist also sends a letter to the physician to explain the program and provides a report of the CMR (the member's PMR and MAP).

Irrespective of participation and completion of a CMR, the PBM pharmacists perform Targeted Medication Reviews (TMRs) for all MTM-qualified non-LTC and LTC members on a quarterly basis. Prescriber outreach is also made via fax or phone based on information derived from the TMRs. Also, PBM pharmacists contact the members by letters or telephone calls depending on the specific TMR alert.

The member will not be disenrolled from the MTMP if they no longer meet all the eligibility criteria and will remain in the MTMP for the remainder of the calendar year.



Follow-up consultations with the PBM pharmacist are scheduled as needed based on each interaction.

CHPW has the ability to complete CMRs and TMRs or complete opt-out requests utilizing the PBMs MTM interface. This is referred to as a "hybrid" platform. The CHPW clinical pharmacist receives training on and utilizes the PBM's proprietary MTM software in a manner that is compliant with CMS, as well as the PBM's internal policies.

CHPW has contracted with an additional vendor to improve MTM access at community pharmacies and clinics. Clinicians in these settings can complete CMRs through the Outcomes platform. The results from these efforts will be aggregated to populate our total CMR completion rate at the end of the year.

#### **Program Oversight and Evaluation**

CHPW routinely reviews MTMP report provided by the PBM to ensure the MTMP meets CMS regulatory requirements.

CHPW also evaluates the report according to the following measures:

- Total number of beneficiaries identified to be eligible for, and automatically enrolled in, the MTMP
- Introductory letter sent within 60 days of qualification in MTMP and offered a CMR including beneficiaries who are in Long Term Care (LTC) settings.
- Total number of beneficiaries who opted-out of enrollment in the MTMP
- The number of beneficiaries who were opted-out of enrollment in the MTMP due to death
- The number of beneficiaries who were opted-out of enrollment in the MTMP due to disenrollment from the Plan
- The number of beneficiaries who opted-out of enrollment in the MTMP at their request
- The number of beneficiaries who opted-out of enrollment in the MTMP for a reason not specified
- The number of beneficiaries offered a CMR
- The number of beneficiaries who received a CMR
- The prescription cost of all covered Part D medications of a member who received a CMR per MTMP criteria during the reporting month



• Number of covered Part D 30-day equivalent prescriptions of a member who received a CMR per MTMP criteria during the reporting month

On an annual basis, CHPW receives a CMS-mandated MTMP report from the PBM for CMS reporting. CHPW reviews and audits the report to ensure the data is accurate and all required reporting data elements are included as outlined in Medicare Part D Technical Specifications and Reporting Requirements documents.

#### **Telephone Consumer Protection Act**

CHPW and the PBM comply with the Telephone Consumer Protection Act passed by Congress in 1991. Delegated staff who perform outbound calls are provided training during the onboarding process on this federal requirement. Recurring training is performed annually thereafter.

The PBM updates a Do Not Call database list on a weekly basis. The PBM relies on one or more of the following to allow calls to members: 1.) an established business relationship; 2.) expressed consent; 3.) the HIPAA exception.

### **List of Appendices**

Attach the appendices themselves on separate pages at the end of the document. If no appendices are attached, replace content in this section and type, "None."

- A. CY 2023 MTMP CMS Submission H5826 Final
- B. Detailed Revision History

| CFR            | 42 CFR § 423.153 |  |  |  |
|----------------|------------------|--|--|--|
| WAC            |                  |  |  |  |
| RCW            |                  |  |  |  |
| LOB & Contract |                  |  |  |  |
| Citation       |                  |  |  |  |
|                | Wraparound       |  |  |  |
|                | □ SMAC           |  |  |  |
|                | □нн              |  |  |  |
|                |                  |  |  |  |
|                | MA/DSNP          | Prescription Drug Benefit Manual Chapter 7 |  |  |
|                |                  |  |  |  |
| Other          |                  |  |  |  |
| Requirements   |                  |  |  |  |
| NCQA Elements  | PHM 7            |  |  |  |

#### **Citations & References**



| F | References |  |  |
|---|------------|--|--|

## **Revision History**

| SME Review: | 10/06/2002; 01/13/2009; 08/05/2009; 09/11/2009; 02/12/2010; |
|-------------|---|
|             | 04/21/2010; 03/14/2011; 03/26/2012; 02/21/2013; 03/24/2014; |
|             | 01/25/2015; 03/10/2016; 03/01/2017; 03/02/2018; 03/08/2019; |
|             | 07/31/2019; 12/18/2019; 02/25/2020; 02/27/2020; 02/23/2021; |
|             | 02/22/2022; 09/14/2022; 09/29/2022; 10/03/2023              |
| Approval:   | 09/09/2009; 04/30/2010; 03/23/2011; 04/04/2012; 04/19/2013; |
|             | 04/23/2014; 03/11/2015; 03.18.2016; 03/14/2017; 03/13/2018; |
|             | 03/13/2019; 03/06/2020; 03/02/2021; 02/28/2022; 10/03/2022; |
|             | 10/26/2023  |



## Appendix A: CY 2023 MTMP - Enter/Edit

# Verify Submission

| Health Plan Managemer   | nt System   | Print Cla   |
|---|---|---|
|   |   | Print Date: 9/14/20   |
| CY 2023 MTM   | P - Reports   |   |
| Status History Re   | eport Detail  |   |
| Contract:   | H5826 - COMM  | UNITY HEALTH PLAN OF WASHINGTON   |
| Version:  | 2   |   |
| Cycle:  | Update Cycle 1  |   |
| Submitted Due to:   | Update Cycle 1  |   |
| Current Status:   | Approved  |   |
| Date Submitted:   | 9/08/2022 3:59  | 29 PM   |
| Submission Date Due:  | 9/10/2022   |   |
| Date Attested:  | 9/08/2022 5:16:   | 24 PM   |
| Attestation Date Due:   | 9/10/2022   |   |
| Multiple Chronic Dise   | ases  |   |
| Minimum number of c<br>Chronic disease(s) tha<br>Chronic disease(s) set   | hronic diseases:<br>at apply:   | 3<br>Specific chronic diseases apply<br>CORE: Bone Disease-Arthritis-Osteoporosis<br>CORE: Chronic Heart Failure (CHF)<br>CORE: Diabetes<br>CORE: Dyslipidemia<br>CORE: End-Stage Renal Disease (ESRD)<br>CORE: Hypertension  |
| Chronic disease(s) tha  | hronic diseases:<br>at apply:   | Specific chronic diseases apply<br>CORE: Bone Disease-Arthritis-Osteoporosis<br>CORE: Chronic Heart Failure (CHF)<br>CORE: Diabetes<br>CORE: Dyslipidemia<br>CORE: End-Stage Renal Disease (ESRD)   |
| Chronic disease(s) tha<br>Chronic disease(s) set<br>Multiple Covered Part   | chronic diseases:<br>at apply:<br>lected:<br><b>t D Drugs</b>   | Specific chronic diseases apply<br>CORE: Bone Disease-Arthritis-Osteoporosis<br>CORE: Chronic Heart Failure (CHF)<br>CORE: Diabetes<br>CORE: Dyslipidemia<br>CORE: End-Stage Renal Disease (ESRD)<br>CORE: Hypertension<br>CORE: Mental Health-Depression<br>CORE: Respiratory Disease-Asthma<br>CORE: Respiratory Disease-Chronic Obstructive Pulmonary Disease (COPD)   |
| Chronic disease(s) tha<br>Chronic disease(s) sel<br>Multiple Covered Part<br>Minimum number of C<br>Drugs:  | chronic diseases:<br>at apply:<br>lected:<br><b>t D Drugs</b><br>Covered Part D                                 | -<br>Specific chronic diseases apply<br>CORE: Bone Disease-Arthritis-Osteoporosis<br>CORE: Chronic Heart Failure (CHF)<br>CORE: Diabetes<br>CORE: Dyslipidemia<br>CORE: End-Stage Renal Disease (ESRD)<br>CORE: Hypertension<br>CORE: Mental Health-Depression<br>CORE: Respiratory Disease-Asthma  |
| Chronic disease(s) tha<br>Chronic disease(s) sel<br>Multiple Covered Part<br>Minimum number of C  | chronic diseases:<br>at apply:<br>lected:<br><b>t D Drugs</b><br>Covered Part D                                 | Specific chronic diseases apply<br>CORE: Bone Disease-Arthritis-Osteoporosis<br>CORE: Chronic Heart Failure (CHF)<br>CORE: Diabetes<br>CORE: Dyslipidemia<br>CORE: End-Stage Renal Disease (ESRD)<br>CORE: Hypertension<br>CORE: Mental Health-Depression<br>CORE: Respiratory Disease-Asthma<br>CORE: Respiratory Disease-Chronic Obstructive Pulmonary Disease (COPD)   |
| Chronic disease(s) tha<br>Chronic disease(s) sel<br>Multiple Covered Part<br>Minimum number of C<br>Drugs:<br>Type of Covered Part I  | chronic diseases:<br>at apply:<br>lected:<br>t <b>D Drugs</b><br>Covered Part D<br>D Drugs that                 | Specific chronic diseases apply<br>CORE: Bone Disease-Arthritis-Osteoporosis<br>CORE: Chronic Heart Failure (CHF)<br>CORE: Diabetes<br>CORE: Dyslipidemia<br>CORE: End-Stage Renal Disease (ESRD)<br>CORE: Hypertension<br>CORE: Mental Health-Depression<br>CORE: Respiratory Disease-Asthma<br>CORE: Respiratory Disease-Chronic Obstructive Pulmonary Disease (COPD)<br>8<br>Chronic/maintenance drugs apply                                     |
| Chronic disease(s) tha<br>Chronic disease(s) sel<br>Multiple Covered Part<br>Minimum number of C<br>Drugs:<br>Type of Covered Part I<br>apply:<br>Incurred Cost for Cow<br>Specific Threshold an                        | chronic diseases:<br>at apply:<br>lected:<br>covered Part D<br>D Drugs that<br>ered Part D Drugs<br>d Frequency | Specific chronic diseases apply<br>CORE: Bone Disease-Arthritis-Osteoporosis<br>CORE: Chronic Heart Failure (CHF)<br>CORE: Diabetes<br>CORE: Dyslipidemia<br>CORE: End-Stage Renal Disease (ESRD)<br>CORE: Hypertension<br>CORE: Mental Health-Depression<br>CORE: Respiratory Disease-Asthma<br>CORE: Respiratory Disease-Chronic Obstructive Pulmonary Disease (COPD)<br>8<br>Chronic/maintenance drugs apply                                     |
| Chronic disease(s) tha<br>Chronic disease(s) sel<br>Multiple Covered Part<br>Minimum number of C<br>Drugs:<br>Type of Covered Part I<br>apply:<br>Incurred Cost for Cow<br>Specific Threshold an                        | chronic diseases:<br>at apply:<br>lected:<br>covered Part D<br>D Drugs that<br>ered Part D Drugs<br>d Frequency | Specific chronic diseases apply<br>CORE: Bone Disease-Arthritis-Osteoporosis<br>CORE: Chronic Heart Failure (CHF)<br>CORE: Diabetes<br>CORE: Dyslipidemia<br>CORE: And-Stage Renal Disease (ESRD)<br>CORE: Hypertension<br>CORE: Mental Health-Depression<br>CORE: Respiratory Disease-Asthma<br>CORE: Respiratory Disease-Asthma<br>CORE: Respiratory Disease-Chronic Obstructive Pulmonary Disease (COPD)<br>8<br>Chronic/maintenance drugs apply |
| Chronic disease(s) tha<br>Chronic disease(s) sel<br>Multiple Covered Part<br>Minimum number of C<br>Drugs:<br>Type of Covered Part I<br>apply:<br>Incurred Cost for Cow<br>Specific Threshold an<br>Incurred one-fourth | chronic diseases:<br>at apply:<br>lected:<br>covered Part D<br>D Drugs that<br>ered Part D Drugs<br>d Frequency | Specific chronic diseases apply<br>CORE: Bone Disease-Arthritis-Osteoporosis<br>CORE: Chronic Heart Failure (CHF)<br>CORE: Diabetes<br>CORE: Dyslipidemia<br>CORE: And-Stage Renal Disease (ESRD)<br>CORE: Hypertension<br>CORE: Mental Health-Depression<br>CORE: Respiratory Disease-Asthma<br>CORE: Respiratory Disease-Asthma<br>CORE: Respiratory Disease-Chronic Obstructive Pulmonary Disease (COPD)<br>8<br>Chronic/maintenance drugs apply |



| 9/14/22, 9:37 AM  | HPMS - CY 2023 MTMP - Reports  |
|---|--|
| Method of enrollment:   | Opt-Out only   |
| Interventions   |  |
| Recipient of interventions:   | Beneficiary<br>Prescriber<br>Caregiver<br>Pharmacy/Pharmacist(s)   |
|   | Interactive, Person-to-Person, Comprehensive Medication Review, annual<br>Interactive, person-to-person or telehealth consultation<br>Face-to-face<br>Phone<br>Telehealth<br>Materials delivered to beneficiary after the interactive, person-to-person<br>CMR consultation<br>Individualized, written summary of CMR in CMS' standardized format<br>(includes beneficiary cover letter, medication action plan, and personal<br>medication list)<br>Delivery of individualized written summary of CMR in CMS' standardized<br>format  |
| Specific beneficiary interventions:   | Mail<br>Fax<br>Email<br>Web Portal Access<br>In-person Delivery Method<br>Other: text message<br>Targeted medication reviews, at least quarterly, with follow-up interventions<br>when necessary<br>Information on the safe disposal of prescription drugs that are controlled<br>substances<br>Method(s) of delivery for the safe disposal information<br>Welcome letter/MTM program enrollment package<br>Other: standardized format   |
| Specific prescriber interventions:  | Prescriber interventions to resolve medication-related problems or optimize<br>therapy<br>Phone consultation<br>Mailed consultation<br>Faxed consultation<br>Emailed consultation<br>Electronic data interchange consultation<br>Other: In person consultation<br>Other: Text consultation<br>Patient Medication list<br>Delivery of a copy of beneficiary CMR summary<br>Other: patient recommended to do list  |
| Specific caregiver interventions:   | Same as beneficiary interventions designated above   |
| Specific pharmacy/pharmacist(s)<br>interventions:   | Same as prescriber interventions designated above  |
| Detailed description of the MTM<br>interventions your program will offer for<br>both beneficiaries and prescribers: | an introductory letter within 60 days that provides an explanation of the program, provides instructions to opt out, offers the opportunity to request a Comprehensive Medication Review (CMR), and includes information on the safe disposal of prescription drugs that are controlled substances, and this includes enrollees who are in long term care (LTC) settings. The member may request a CMR by calling the provided toll free number. Members that request a CMR by calling the provided toll free number. Members that request a CMR by calling the provided toll free number. Members that request a CMR will be contacted for a one on one consultation with a qualified MTM provider. We may also attempt to contact qualified members, or their caregivers, via phone, text, or other electronic method of communication to offer their CMR within 60 days of qualification. Meanwhile, all members that have not opted out of the program receive ongoing Targeted Medication Reviews (TMRs) on at least a quarterly basis with each update of prescription claims. TMRs identify opportunities for interventions based on systematic drug utilization review and may include cost savings, adherence to national consensus treatment |
| https://hpms.cms.gov/app/MTM2023/reports/history/St   | atusHistoryReportSub.aspx?PI=150423400082&CID=H5826&VER=2 2/5  |



9/14/22, 9:37 AM HPMS - CY 2023 MTMP - Reports guidelines, adherence to prescribed medication regimens, and safety concerns. TMRs that identify drug therapy problems are categorized and triaged based on the severity of the problem. The member, caregiver, or prescriber is then contacted in person or via phone, text, mail, email, electronic data exchange, or fax as appropriate for review of potential drug therapy changes. TMR generated intervention opportunities that result in outreach to the member or caregiver may allow an additional opportunity for the MTM vendor to offer the member or caregiver a CMR. Members or caregivers that accept the CMR receive the CMR as outlined below. Additionally, members, or their caregivers, may receive a CMR offer and or have the opportunity to complete a CMR with a qualified MTM provider while at their provider office, pharmacy, or LTC facility. In addition, LTC facility information may be provided to assist in outreach to LTC members or their caregivers. CMRs may also be completed directly with the prescriber over the phone, through telehealth, or face to face in the prescriber office if the beneficiary is cognitively impaired. Interventions resulting from person to person TMRs, non person to person TMRs, and CMRs may result in prescriber contact in person or via fax, phone, text, email, electronic data exchange, or mail, when appropriate. Detailed description of your MTM Comprehensive Medication Reviews (CMRs) are completed as a one on one program's annual comprehensive consultation with a qualified MTM provider. CMR completion will be via medication review, including an telephone, telehealth or face to face. During the CMR, the entire medication interactive, person-to-person, or profile for the member is reviewed (including prescriptions, OTCs, herbal telehealth consultation and the provision supplements and samples) for appropriateness of therapy. The purpose and of an individualized, written summary in direction of each medication are reviewed with the recipient of the CMR and CMS' standardized format: documented on the Personal Medication List (PML). Disease specific goals of therapy and medication related problems may be discussed, as well as any specific questions. After the CMR, the member is provided the standardized post CMR takeaway letter which includes a Recommended To-Do List detailing the conversation with the MTM provider and a PML through mail, fax, email, web portal access, text message, or in person delivery. Detailed description of how your MTM All members that have not opted out of the program receive ongoing Targeted program will perform targeted medication Medication Reviews (TMRs) on at least a quarterly basis with each prescription reviews, at least quarterly, with follow-up claim update and each time the member should have a prescription claim for a interventions when necessary; chronic medication. At the end of each quarter, all enrolled members are reviewed to ensure that a TMR was performed that quarter. If a TMR was not performed due to not receiving any prescription claims for the member during that quarter, the system will complete a TMR in the absence of new claims to ensure compliance. TMRs identify opportunities for interventions based on systematic drug utilization review and may include cost savings, adherence to national consensus treatment guidelines, adherence to prescribed medication regimens, and safety concerns. TMRs that identify drug therapy problems are categorized and triaged based on the severity of the alert. The member, caregiver, or prescriber is then contacted in person or via phone, text, mail email, electronic data exchange, or fax as appropriate for review of potential drug therapy changes. TMR alerts that result in outreach to the member or caregiver may allow an additional opportunity for the MTM vendor to offer the member or caregiver a CMR. Members or caregivers that accept the CMR receive the CMR as outlined above. Interventions resulting from person to person TMRs, non person to person TMRs, and CMRs may result in prescriber contact in person or via fax, phone, text, email, electronic data exchange, or mail, when appropriate Detailed description of how your MTM Every member who qualifies for the MTMP will receive information regarding program will provide enrollees with the safe disposal of prescription drugs that are controlled substances, drug take back programs, in home disposal and cost effective means to safely information regarding the safe disposal of prescription drugs that are controlled dispose of such drugs in their introductory letter that is sent within 60 days of substances, drug take back programs, inqualification into the program. If we do not have contact information on file for home disposal and cost-effective means the member, or we have a history of bad contact information, we will send the to safely dispose of such drugs: introductory letter if updated contact information is received. Detailed description of any other value added MTM services that your MTM program will offer: Change Request Field Description: updated formatting due to a copy paste error.

https://hpms.cms.gov/app/MTM2023/reports/history/StatusHistoryReportSub.aspx?PI=150423400082&CID=H5826&VER=2

3/5



| 2, 9:37 AM  | HPMS - CY 2023 MTMP - Reports  |
|---|--|
| Resources   |  |
| Provider of MTM services:   |  |
| In-house staff  |  |
| Pharmacist  |  |
| Outside personnel<br>Medication Therapy Management vendor   |  |
| Name of vendor: Tabula Rasa health care group   |  |
| In-house Pharmacists  |  |
| Local Pharmacists   |  |
| Long Term Care Consultant Pharmacist  |  |
| Physician   |  |
| Registered Nurse<br>Licensed Practical Nurse  |  |
| Nurse Practitioner  |  |
| Physician's Assistant   |  |
| Pharmacy intern under the direct supervision of a   |  |
| pharmacist  |  |
| Pharmacy technician<br>Name of vendor: Outcomes incorporated  |  |
| In-house Pharmacists  |  |
| Local Pharmacists   |  |
| Physician   |  |
| Registered Nurse  |  |
| Nurse Practitioner<br>Physician's Assistant   |  |
| Pharmacy intern under the direct supervision of a   |  |
| pharmacist  |  |
| Other: MTM vendor pharmacist  |  |
| Qualified Provider of Interactive, Person-to-Person Cl  | MR with written summaries:   |
| Physician   |  |
| Registered Nurse  |  |
| Licensed Practical Nurse  |  |
| Plan Sponsor Pharmacist<br>MTM Vendor Local Pharmacist  |  |
| MTM Vendor In-house Pharmacist  |  |
| MTM Vendor Long Term Care Consultant Phamacist  |  |
| Nurse Practitioner  |  |
| Physician's Assistant   |  |
| Pharmacy intern under the direct supervision of a   |  |
| pharmacist<br>Other: MTM vendor pharmacist  |  |
| Change Request Field Description:   | adding plan sponsor in house pharmacist to support with Cl   |
| change Request Field Description.   | completions.   |
| Fees  |  |
| Medication Therapy Management vendor: Fees are cov  | ered as part of the services of the Medication Therapy Manage  |
| vendor contract without being priced out separately   |  |
| Outcomes Measured   |  |
| Part D Reporting Requirements<br>Medication issues resolved   |  |
| Cost avoidance savings<br>Member satisfaction   |  |
| Additional Information 1  |  |
| Description: To promote continuity of care for MTM me   | embers qualified in previous years, and to qualify new member  |
| early in the program year as possible, pre<br>qualification.Frequency of eligibility crite<br>as stated in the Targeting section. Eligibi | vious year prescription claims are used when available to deter<br>ria analysis will be determined by the Medicare Part D plan spo<br>lity determination will occur as early in the year as possible and |
| setup, eligibility determination occurs wit   | ecified last eligibility analysis date. Following the initial progra<br>the ach data feed provided by the plan sponsor or their<br>sting has been selected. Targeted Medication reviews are              |

representative, unless less frequent targeting has been selected. Targeted Medication reviews are



#### 9/14/22, 9:37 AM

#### HPMS - CY 2023 MTMP - Reports

completed at least quarterly, or with each update of prescription claims, and continue throughout the year until the specified last analysis date.Furthermore, additional modes of support are provided to ensure accessibility and care delivery to members. This includes, but not limited to, TTY services, capability to print in braille, language support in hundreds of languages via a language translation line, and coordination of care between case management and long-term care facilities.

#### Additional Information 2

Description:

^□



| 22, 9:37 AM  |   | HPMS - CY 2023 MTMP - Reports  |
|--|---|--|
| HPMS<br>Health Plan Management   | nt System                                   | Print   Clos   |
|  |   | Print Date: 9/14/202   |
| CY 2023 MTM  | P - Reports                                 |  |
|  |   |  |
| Status History R   | eport Detail                                |  |
| Contract:  | H5826 - COMMI                               | JNITY HEALTH PLAN OF WASHINGTON  |
| Version:   | 2   |  |
| Cycle:   | Update Cycle 1                              |  |
| Submitted Due to:  | Update Cycle 1                              |  |
| Current Status:  | Approved                                    |  |
| Date Submitted:  | 9/08/2022 3:59:                             | 29 PM  |
| Submission Date Due:   | 9/10/2022                                   |  |
| Date Attested:   | 9/08/2022 5:16:2                            | 24 PM  |
| Attestation Date Due:  | 9/10/2022                                   |  |
| Targeting Criteria for<br>MTM Program offered  |   | NTMP<br>Only enrollees who meet the specified targeting criteria per CMS requirements  |
| Multiple Chronic Dise  |   | Only enrollees who meet the spectned targeting criteria per CMS requirements   |
| Minimum number of c  |   | 3  |
| Chronic disease(s) that  |   | Specific chronic diseases apply  |
| Chronic disease(s) sel   |   | CORE: Bone Disease-Arthritis-Osteoporosis<br>CORE: Chronic Heart Failure (CHF)<br>CORE: Diabetes<br>CORE: Dyslipidemia<br>CORE: End-Stage Renal Disease (ESRD)<br>CORE: Hypertension<br>CORE: Hypertension<br>CORE: Mental Health-Depression<br>CORE: Respiratory Disease-Asthma<br>CORE: Respiratory Disease-Chronic Obstructive Pulmonary Disease (COPD) |
| Multiple Covered Par   | t D Drugs                                   |  |
| Minimum number of C<br>Drugs:  | overed Part D                               | 8  |
| Type of Covered Part   | D Drugs that                                | Chronic/maintenance drugs apply  |
| apply:   |   |  |
|  | ered Part D Drugs                           |  |
| apply:<br>Incurred Cost for Cov<br>Specific Threshold an   | d Frequency                                 | al cost threshold (\$4,935) in previous three months   |
| apply:<br>Incurred Cost for Cov<br>Specific Threshold an   | d Frequency                                 | al cost threshold (\$4,935) in previous three months   |
| apply:<br>Incurred Cost for Cow<br>Specific Threshold an<br>Incurred one-fourth                            | d Frequency                                 | al cost threshold (\$4,935) in previous three months<br>Weekly   |
| apply:<br>Incurred Cost for Cow<br>Specific Threshold an<br>Incurred one-fourth<br>Targeting               | d Frequency<br>of specified annu            | Weekly<br>Drug claims  |
| apply:<br>Incurred Cost for Cow<br>Specific Threshold an<br>Incurred one-fourth<br>Targeting<br>Frequency: | d Frequency<br>of specified annu<br>geting: | Weekly   |



## **Appendix B: Detailed Revision History**

| Revision Date | Revision Description                    | <b>Revision Made By</b> |
|---------------|---|-------------------------|
| 10/26/2006    | Minor Formatting                        | Rachel Koh              |
| 01/13/2009    | Review for style and formatting         | Sunny Otake             |
| 08/05/2009    | Content Update                          | Jennifer Mui            |
| 09/09/2009    | Approval                                | MMLT                    |
| 09/11/2009    | Edit for clarity and style; reformat    | Jennifer Carlisle       |
| 02/12/2010    | Content Update                          | Maria Chan              |
| 04/21/2010    | Content Update                          | Maria Chan              |
| 04/30/2010    | Approval                                | MMLT                    |
| 03/14/2011    | Content Update                          | Maria Chan              |
| 03/23/2011    | Approval                                | MMLT                    |
| 03/26/2012    | Content Update on MTMP process          | Maria Chan              |
| 04/04/2012    | Approval                                | MMLT                    |
| 02/21/2013    | Content Update on MTMP process          | Maria Chan              |
| 04/19/2013    | Approval                                | MMLT                    |
| 03/24/2014    | Review and content update               | Annie Lam               |
| 04/23/2014    | Approval                                | MMLT                    |
| 01/25/2015    | Review with no changes                  | Lauren Pope             |
| 03/11/2015    | Approval                                | MMLT                    |
| 03/10/2016    | Added Telephone consumer Protection     | Mary Eckhart            |
|               | Act section                             |                         |
| 03/18/2016    | Approval                                | MMLT                    |
| 03/01/2017    | Moved to new template                   | Mary Eckhart            |
| 03/14/2017    | Approval                                | MMLT                    |
| 03/02/2018    | Moved to new template.                  | Mary Eckhart            |
| 03/13/2018    | Approval                                | MMLT                    |
| 03/08/2019    | Minor changes                           | Rebecka Braband         |
| 03/13/2019    | Approval                                | MMLT                    |
| 07/31/2019    | No Changes. Updated Citations table.    | Rebecka Braband         |
| 12/18/2019    | Updated number of minimum               | Fran McGaugh            |
|               | medications                             |                         |
| 02/25/2020    | Reviewed. Updated Citations table       | Rebecka Braband         |
| 02/27/2020    | Reviewed. Added explanation of the role | Ivan Figueira           |
|               | of the CHPW clinical pharmacist.        |                         |
| 02/28/2020    | Reviewed and approved                   | Omar Daoud              |
| 3/6/2020      | Approved                                | Yusuf Rashid            |



| 03/06/2020 | Approval                             | CMO Cabinet       |
|------------|--------------------------------------|-------------------|
| 02/23/2021 | Updated appendix                     | Erin Riddle       |
| 02/23/2021 | Reviewed                             | Omar Daoud        |
| 03/01/2021 | Approval                             | Yusuf Rashid      |
| 03/02/2021 | Approval                             | CMO Cabinet       |
| 02/22/2022 | Reviewed, no changes. Department     | Omar Daoud        |
|            | approval.                            |                   |
| 02/28/2022 | Approval                             | CMO Cabinet       |
| 09/14/2022 | Reviewed. Added Outcomes vendor      | Erin Riddle       |
| 09/29/2022 | Approved                             | Omar Daoud        |
| 10/03/2022 | Approval                             | CMO Cabinet       |
| 10/03/2023 | Reviewed. Added calls supplementing  | Brittney Kessel   |
|            | letters in offering CMR or opt-out.  |                   |
| 10/24/2023 | Reviewed the updates and no concerns | Omar Daoud        |
| 10/26/2023 | Approved                             | Clinical Services |
|            |                                      | Leadership Team   |
| 01/22/2025 | No changes                           | Omar Daoud        |
| 01/24/2025 | Approved                             | Clinical Services |
|            |                                      | Leadership Team   |
|            |                                      |                   |